We are proud to participate in the ASP’s STRIPE initiative. It is a continuing forum where public and private sector members work together to achieve common objectives and leverage collective opportunities to accelerate the development of precision medicine practices as a standard of care. With the standardization of pharmacogenomics testing as a goal, it will result in accurate and reliable information about a patient’s medication and drug-gene interactions. This standardization will ultimately have a direct effect on reducing the number of deaths from 5-FU and capecitabine.
For more information on these two initiatives, please visit the ASP website: https://www.stopadr.org/stripe